Tweet

Comments (0)

Related articles and links |  1 of 2

This article originally appeared in Christianity Today on January 10, 1994.

It finally happened. Researchers at George Washington University successfully cloned human embryos last October. The experiment, the first of its kind to be reported, was intended to enhance current in-vitro fertilization methods. The result, however, has reinforced our greatest fears about biomedical research: It can—and will—do anything, regardless of moral or ethical questions. It is time to insist that a deliberate and careful process be established to guide biomedical technology.

Cloning may attract the most attention, but other questionable biomedical practices have become almost commonplace. For example, in Virginia, a child born a year ago without most of her brain is being kept alive on a ventilator. The child, dubbed "Baby K," cannot think, see, hear, or feel, yet receives care at her mother's insistence (against the advice of hospital officials). The hospital has taken the matter to court.

In 1991, the National Institutes of Health sought to patent over 2,000 gene sequences from human brain DNA. Many of us were astounded to learn that the United States Patent Office, aided only by centuries-old patent law, could offer such protection. The requests are still pending.

Almost daily we learn of startling and wondrous developments in our ability to control nearly every facet of human life. Such control—whether through efforts to lengthen life (or end it) or to create it in controlled laboratories—is becoming more readily available at a rapid pace. Despite the obvious benefits, some developments have begun to alarm researchers, ethicists, religious groups, and laypeople across the country. Each technological advance propels us into unfamiliar ethical territory. We are left groping for ethical guidance to accompany our new-found knowledge. So far, we have received little.

Elected officials have a certain responsibility to raise these concerns and to ensure that thoughtful dialogue takes place. In the past, I have called for a moratorium on patenting human and animal mailer in order to provide time for a rational discussion of the profound questions raised by genetic engineering, and proposals to patent life. But simply clamping down on patenting of scientific research is not a solution.

What is most disturbing about our attempts to resolve these ethical issues is that we do not even have a framework for discussing them. We do not even have consensus on where the cases should be examined: the Baby M surrogate motherhood case was heard in state civil court using slate contract law; Dr. Jack Kevorkian has been challenged under state criminal law; even the U.S. Patent Office, of all places, has been drawn into these dilemmas. Where does proper authority lie?

The first step is to build a shared framework for addressing these questions. To that end, I have posed that Congress establish a 15-member Ethics Advisory Board that would be charged with the task of reviewing issues of biomedical ethics and advising Congress and the President. Such a board will not only provide ethical guidance to policymakers, but will help increase nationwide dialogue on the important bioethical issues before us.

The Office of Technology Assessment recently found that the United States is virtually alone in the industrialized world in not having such a commission. The reestablishment of a permanent commission is not a universally supported idea. Students of this issue know that past attempts have taken place with mixed results. We have learned much from the past, however.

next page... |  1 of 2

January 10 1994, Vol. 38, No. 1